We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed's New Brightree Suite to Boost Home Infusion Business
Read MoreHide Full Article
Brightree, the wholly owned subsidiary of ResMed Inc. (RMD - Free Report) , recently announced a new and enhanced pharmacy suite, which will cater to home infusion therapy providers and home medical equipment (HME) pharmacies. The company plans to showcase this pharmacy suite at NHIA 2019.
Per ResMed, this improved suite will help optimize business processes of the users by easily meeting compliance requirements and providing them with highest quality patient care. Bringing automation into the home infusion and HME pharmacy work flow, this suite is supposed to create a seamless connection with leading electronic health/medical records (EHR/EMR) and third-party vendors to receive necessary patient data and process medication prescriptions electronically.
Brightree Prospects at a Glance
Significantly, ResMed’s Brightree software-as-a-service business is gradually growing strong. This business has been part of the ResMed Group for three full years, having registered a stable period of success. On the last reported second-quarter fiscal 2019 conference call, ResMed noted that the Software-as-a-Service portfolio continues with its trajectory of excellent growth registering 63% higher revenues year over year, driven by a steady expansion of Brightree and the full quarterly contribution from HEALTHCAREfirst along with partial quarterly benefits from MatrixCare and Apacheta.
While the MatrixCare buyout was closed last November, the technology tuck-in acquisition of Apacheta was completed of late, which bode well for growth in the Brightree business.
Analyzing the HME market prospects, we expect this growth momentum to sustain in the long run. According to an article by Freedonia Group, US demand for home medical equipment in 2018 is likely to gain 8.2% to $12.6 billion, driven by technological advances and cost-containment efforts.
Share Price Performance
In the past three months, shares of ResMed have underperformed its industry. The stock has declined 11% versus the 4.8% growth of the industry.
ABIOMED’s long-term earnings growth rate is expected to be 27.67%.
Penumbra’s long-term earnings growth rate is projected at 20.93%.
Masimo’s long-term earnings are projected to grow 15.60%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
ResMed's New Brightree Suite to Boost Home Infusion Business
Brightree, the wholly owned subsidiary of ResMed Inc. (RMD - Free Report) , recently announced a new and enhanced pharmacy suite, which will cater to home infusion therapy providers and home medical equipment (HME) pharmacies. The company plans to showcase this pharmacy suite at NHIA 2019.
Per ResMed, this improved suite will help optimize business processes of the users by easily meeting compliance requirements and providing them with highest quality patient care. Bringing automation into the home infusion and HME pharmacy work flow, this suite is supposed to create a seamless connection with leading electronic health/medical records (EHR/EMR) and third-party vendors to receive necessary patient data and process medication prescriptions electronically.
Brightree Prospects at a Glance
Significantly, ResMed’s Brightree software-as-a-service business is gradually growing strong. This business has been part of the ResMed Group for three full years, having registered a stable period of success. On the last reported second-quarter fiscal 2019 conference call, ResMed noted that the Software-as-a-Service portfolio continues with its trajectory of excellent growth registering 63% higher revenues year over year, driven by a steady expansion of Brightree and the full quarterly contribution from HEALTHCAREfirst along with partial quarterly benefits from MatrixCare and Apacheta.
ResMed Inc. Price
ResMed Inc. Price | ResMed Inc. Quote
While the MatrixCare buyout was closed last November, the technology tuck-in acquisition of Apacheta was completed of late, which bode well for growth in the Brightree business.
Analyzing the HME market prospects, we expect this growth momentum to sustain in the long run. According to an article by Freedonia Group, US demand for home medical equipment in 2018 is likely to gain 8.2% to $12.6 billion, driven by technological advances and cost-containment efforts.
Share Price Performance
In the past three months, shares of ResMed have underperformed its industry. The stock has declined 11% versus the 4.8% growth of the industry.
Zacks Rank and Key Picks
ResMed currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are ABIOMED, Inc., , Penumbra, Inc., (PEN - Free Report) and Masimo, Inc. (MASI - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
ABIOMED’s long-term earnings growth rate is expected to be 27.67%.
Penumbra’s long-term earnings growth rate is projected at 20.93%.
Masimo’s long-term earnings are projected to grow 15.60%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>